Table 2.
Accuracy rate and rate of each unanswered question
| Questions | Correct responses | Unanswered | ||
|---|---|---|---|---|
| n | % (95% CI) | n | % | |
| 1. Time window for intravenous fibrinolysis | 85 | 64.9 (56.02–72.89) | 1 | 0.8 |
| 2. Imaging results required before fibrinolysis | 109 | 83.2 (75.45–88.95) | 0 | 0 |
| 3. Laboratory results required before fibrinolysis | 1 | 0.8 (0.05–4.87) | 0 | 0 |
| 4. Dose of alteplase | 87 | 66.4 (57.55–74.27) | 3 | 2.3 |
| 5. Maximum dose of alteplase | 67 | 51.1 (42.26–59.88) | 4 | 3.1 |
| 6. Whether to thrombolyse if hypodensity > 1/3 MCA territory on CT | 126 | 96.2 (90.89–98.6) | 3 | 2.3 |
| 7. Whether to thrombolyse if patients had prior ischemic stroke within 2 months | 84 | 64.1 (55.20–72.16) | 2 | 1.5 |
| 8. Whether to thrombolyse if patients had previous intracranial hemorrhage | 69 | 52.7 (43.82–61.42) | 5 | 3.8 |
| 9. Whether to thrombolyse if NIHSS > 25 within 3 h from symptom onset | 45 | 34.4 (26.46–43.27) | 2 | 1.5 |
| 10. Whether to stop thrombolyse if patients develop skin, mucosa or gum bleeding | 62 | 47.3 (38.58–56.18) | 1 | 0.8 |
| 11. Whether to stop thrombolyse if patients develop severe vomiting | 42 | 32.1 (24.37–40.9) | 1 | 0.8 |
| 12. Whether to stop thrombolyse if patients develop worsening neurological examinations | 86 | 65.6 (56.73–73.54) | 1 | 0.8 |
MCA middle cerebral artery, CT computed tomography